Výsledky vyhledávání - "Ritchlin, CT"

Akademický článek

Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation

Autor: Bawany F, Ryan Wolff J, Ritchlin CT, Tausk F

Publikováno v: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 1175-1180 (2023)

Fatima Bawany,1 Julie Ryan Wolff,1 Christopher T Ritchlin,2 Francisco Tausk1,2 1Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA; 2Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA

Externí odkaz: https://doaj.org/article/66ab580221394e399bbb78465015b634

Zobrazit plný text záznamu

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Autor: Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

Publikováno v: The Lancet, 401(10370), 38-48. Elsevier Limited

Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea85d6610989d71234565312cb4eed4
https://doi.org/10.1016/s0140-6736(22)02303-0

Zobrazit plný text záznamu

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study

Autor: Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R

Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::0ae8f298a66cfb33a4fb1de689e01e8c
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad

Zobrazit plný text záznamu

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study

Autor: Orbai, A-M, Coates, LC, Deodhar, A, Helliwell, PS, Ritchlin, CT, Leibowitz, E, Kollmeier, AP, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Objective The Phase 3 DISCOVER-1 study of guselkumab is the first randomized controlled trial to use Patient-Reported Outcomes Measurement Information System (PROMIS) measures to assess the effects of treatment on general health outcomes in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed54840ac2fdd984d0f0b0cffe2bef1a
https://eprints.whiterose.ac.uk/189644/1/s40271-022-00588-6.pdf

Zobrazit plný text záznamu

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free

Autor: Coates, LC, Ritchlin, CT, Gossec, L, Helliwell, P, Rahman, P, Hsia, EC, Kollmeier, A, Xu, XL, Karyekar, C, Shawi, M, Noel, W, Jiang, Y, Sheng, S, Wang, Y, Mease, PJ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::c02d2b289a4434dcecd7cb2fb49c133d
https://doi.org/10.1136/annrheumdis-2021-eular.167

Zobrazit plný text záznamu

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial

Autor: Orbai, AM, Coates, LC, Deodhar, A, Helliwell, P, Ritchlin, CT, Kollmeier, A, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::f8dcb3bf58c68b4bf023496ec3b84582
https://doi.org/10.1136/annrheumdis-2021-eular.471

Zobrazit plný text záznamu

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity

Autor: Mease, PJ, Gladman, DD, Collier, D, Ritchlin, CT, Helliwell, P, Coates, LC, Strand, V, Liu, L, Kricorian, G, Chung, J

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::ae2f5d43ca62858ef940b558b81da421
https://doi.org/10.1136/annrheumdis-2019-eular.783

Zobrazit plný text záznamu

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials

Autor: McInnes, IB, Puig, L, Gottlieb, AB, Ritchlin, CT, Song, M, You, Y, Kafka, S, Morgan, GJ, Rahman, P, Kavanaugh, A, PSUMMIT 1 Study Grp, PSUMMIT 2 Study Grp

Publikováno v: JOURNAL OF RHEUMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Objective. Evaluate enthesitis, physical function, and health-related quality of life (HRQOL) among patients with psoriatic arthritis (PsA) who are naive to anti-tumor necrosis factor agents. Methods. In PSUMMIT 1 and 2, patients with PsA were random

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::54d79b0fd7ae130efebfec305ba98b7c
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2388

Zobrazit plný text záznamu

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept

Autor: Choy, EHS, Gladman, DD, Mease, PJ, Wordsworth, P, Ritchlin, CT, Wang, H, Sasso, EH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::812b0095e72fb9c04c6632174ff5cccd
https://ora.ox.ac.uk/objects/uuid:38c7963d-8407-4b3a-a5eb-a3b39eda68cc

Zobrazit plný text záznamu

Treatment recommendations for psoriatic arthritis

Autor: Ritchlin, CT, Kavanaugh, A, Gladman, DD, Mease, PJ, Helliwell, P, Boehncke, W-H, de Vlam, K, Fiorentino, D, FitzGerald, O, Gottlieb, AB, McHugh, NJ, Nash, P, Qureshi, AA, Soriano, ER, Taylor, WJ, GRAPPA

Publikováno v: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 68, No 9 (2009) pp. 1387-1394

Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion. Methods: Forma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6b46c713364a7b64c24c0a783e8a92
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/7463

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání